JPWO2022124282A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022124282A5
JPWO2022124282A5 JP2022568277A JP2022568277A JPWO2022124282A5 JP WO2022124282 A5 JPWO2022124282 A5 JP WO2022124282A5 JP 2022568277 A JP2022568277 A JP 2022568277A JP 2022568277 A JP2022568277 A JP 2022568277A JP WO2022124282 A5 JPWO2022124282 A5 JP WO2022124282A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
sequence shown
prame
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022568277A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022124282A1 (https=
JP7785361B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2021/044807 external-priority patent/WO2022124282A1/ja
Publication of JPWO2022124282A1 publication Critical patent/JPWO2022124282A1/ja
Publication of JPWO2022124282A5 publication Critical patent/JPWO2022124282A5/ja
Application granted granted Critical
Publication of JP7785361B2 publication Critical patent/JP7785361B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022568277A 2020-12-10 2021-12-07 Ｐｒａｍｅ結合性分子 Active JP7785361B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020205384 2020-12-10
JP2020205384 2020-12-10
PCT/JP2021/044807 WO2022124282A1 (ja) 2020-12-10 2021-12-07 Ｐｒａｍｅ結合性分子

Publications (3)

Publication Number Publication Date
JPWO2022124282A1 JPWO2022124282A1 (https=) 2022-06-16
JPWO2022124282A5 true JPWO2022124282A5 (https=) 2023-10-24
JP7785361B2 JP7785361B2 (ja) 2025-12-15

Family

ID=81974443

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568277A Active JP7785361B2 (ja) 2020-12-10 2021-12-07 Ｐｒａｍｅ結合性分子

Country Status (6)

Country Link
US (1) US20240024480A1 (https=)
EP (1) EP4260870A4 (https=)
JP (1) JP7785361B2 (https=)
KR (1) KR20230118874A (https=)
CN (1) CN116710136A (https=)
WO (1) WO2022124282A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118221811B (zh) * 2023-08-25 2025-05-30 立凌生物制药(苏州)有限公司 靶向prame多肽的单域抗体及其用途
WO2025047925A1 (ja) * 2023-08-31 2025-03-06 国立大学法人三重大学 ハイブリッドｔ細胞受容体
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201702272A (zh) * 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
CN106478809B (zh) * 2015-11-06 2018-06-01 广东香雪精准医疗技术有限公司 识别prame抗原短肽的tcr

Similar Documents

Publication Publication Date Title
JPWO2022124282A5 (https=)
JP2018520657A5 (https=)
JP2016536322A5 (https=)
JP2017536341A5 (https=)
RU2016106577A (ru) САЙТЫ АНТИТЕЛ, СПЕЦИФИЧНО СВЯЗЫВАЮЩИЕ EGFRvIII
RU2016100892A (ru) Антитела против tweakr и их применение
JP2009225799A5 (https=)
JP2020525032A5 (https=)
HRP20251181T1 (hr) Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene
JP2012525829A5 (https=)
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
JP2019515646A5 (https=)
FI3129404T3 (fi) Ihmisen vgamma9vdelta2-t-solureseptoreita sitovia immunoglobuliineja
NZ750366A (en) Chimeric antigen receptors targeting bcma and methods of use thereof
JP2013538057A5 (https=)
EP4464333A3 (en) Anti-death receptor antibodies and methods of use thereof
HRP20201375T1 (hr) ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE
JP2012522523A5 (https=)
JP2018516554A5 (https=)
JP2016507523A5 (https=)
JP2014526898A5 (https=)
HRP20120701T1 (hr) Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1
JP2017504578A5 (https=)
JP2017505125A5 (https=)
CL2010000096A1 (es) Anticuerpo monoclonal o una porción que se une al antígeno del mismo que se une a alk-1, molécula de acido nucleico codificante; composición farmaceutica que lo comprende; uso de dicho anticuerpo para preparar un medicamento útil para inhibir la angiogénesis en un mamifero. (div.sol.2333-06).